Neurologic disorders are prevalent diseases in the population and represent a major cause of
death and disability. Despite the advances made during recent decades, the early diagnosis of these
diseases remains a challenge. Determining the pathophysiology of such disorders is also challenging
and is a requirement for the development of new drugs and treatments. Molecular neuroimaging studies
can help fill these gaps in knowledge by providing clinicians with the tools necessary to diagnose
and monitor treatment response and by providing data to help researchers understand the mechanisms
of disease. Molecular imaging is a fast-growing field of research, and the development of imaging probes is crucial to molecular
imaging research. Imaging based on peptide and small protein molecular probes provides many advantages over
traditional neuroimaging for the identification of many pathological aspects of nervous diseases, especially gliomas, for
which this type of imaging is gradually being moved to clinical settings. Nonetheless, peptide and small protein imaging
also has potential applications in other neurologic diseases such as stroke, Parkinson’s disease and Alzheimer’s disease.
This review is focused on the main peptide and small protein probes used for molecular imaging in neurologic disease.
Keywords: Glioma, Molecular imaging, Neurologic diseases, Peptide, PET, Probe, Small protein, SPECT.
Rights & PermissionsPrintExport